Scars: A review of emerging and currently available therapies

Plastic and Reconstructive Surgery

Volumn 122, Issue 4, 2008, Pages 1068-1078

  Reish, Richard G ^a   Eriksson, Elof ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BLEOMYCIN; COLLAGEN; CORTICOSTEROID; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBROMODULIN; FIBRONECTIN; FLUOROURACIL; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; PROCOLLAGEN C PROTEINASE INHIBITOR; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE INHIBITOR; PROTEIN SYNTHESIS INHIBITOR; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA3; SILICONE GEL; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRANSFORMING GROWTH FACTOR BETA1 ANTIBODY; TRANSFORMING GROWTH FACTOR BETA2 ANTIBODY; TRIAMCINOLONE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPRESSION THERAPY; CRYOTHERAPY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; EVIDENCE BASED MEDICINE; GENE EXPRESSION; GENE THERAPY; HUMAN; HYPERPIGMENTATION; HYPERTROPHIC SCAR; HYPOPIGMENTATION; KELOID; LOW DRUG DOSE; LOW LEVEL LASER THERAPY; MEDICAL LITERATURE; MEDLINE; MONOTHERAPY; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULSED DYE LASER; PURPURA; REVIEW; SCAR FORMATION; SKIN ATROPHY; SKIN SURGERY; SKIN TRANSPLANTATION; TELANGIECTASIA; TISSUE EXPANSION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WOUND HEALING; WOUND HEALING IMPAIRMENT; BANDAGE; PHYSIOLOGY; PRESSURE; SCAR; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; BANDAGES; CICATRIX; CRYOTHERAPY; GENE THERAPY; HUMANS; LASER THERAPY; PRESSURE; SILICONE GELS; WOUND HEALING;

EID: 53149149431     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/PRS.0b013e318185d38f     Document Type: Review

References (115)

1. Singer, A. J., and Clark, R. A. Cutaneous wound healing. N. Engl. J. Med. 341: 738, 1999.
2. Reish, R. G., and Eriksson, E. Scar treatments: Preclinical and clinical studies. J. Am. Coll. Surg. 206: 719, 2008.
3. Rockwell,W. B., Cohen, I.K., and Ehrlich, H.P. Keloids and hypertrophic scars: A comprehensive review. Plast. Reconstr. Surg. 84: 827, 1989.
4. Pierce, G. F., Tarpley, J. E., Yanagihara, D., Mustoe, T. A., Fox,G.M., and Thomason,A.Platelet-derived growth factor (BB homodimer), transforming growth factor-beta 1, and basic fibroblast growth factor in dermal wound healing: Neovessel and matrix formation and cessation of repair. Am. J. Pathol. 140: 1375, 1992.
5. Pierce, G. F., Vande Berg, J., Rudolph, R., Tarpley, J., and Mustoe, T. A. Platelet-derived growth factor-BB and transforming growth factor beta 1 selectively modulate glycosaminoglycans, collagen, and myofibroblasts in excisional wounds. Am. J. Pathol. 138: 629, 1991.
6. Niessen, F. B., Andriessen, M. P., Schalkwijk, J., et al. Keratinocyte-derived growth factors play a role in the formation of hypertrophic scars. J. Pathol. 194: 207, 2001.
7. Mast, B. A., Diegelmann, R. F., Krummel, T. M., and Cohen, I. K. Scarless wound healing in the mammalian fetus. Surg. Gynecol. Obstet. 174: 441, 1992.
8. Lin, R. Y., Sullivan, K. M., Argenta, P. A., Meuli, M., Lorenz, H. P., and Adzick, N. S. Exogenous transforming growth factor-beta amplifies its own expression and induces scar formation in a model of human fetal skin repair. Ann. Surg. 222: 146, 1995.
9. Peled, Z. M., Warren, S. M., Bouletreau, P. J., and Longaker, M. T. Methods for investigating fetal tissue repair. Methods Mol. Med. 78: 149, 2003.
10. Roberts, A. B., Sporn, M. B., Assoian, R. K., et al. Transforming growth factor type beta: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc. Natl. Acad. Sci. U.S.A. 83: 4167, 1986.
11. Chen, W., Fu, X., Ge, S., et al. Ontogeny of expression of transforming growth factor-β and its receptors and their possible relationship with scarless healing in human fetal skin. Wound Repair Regen. 13: 68, 2005.
12. Whitby, D. J., and Ferguson, M. W. Immunohistochemical localization of growth factors in fetal wound healing. Dev. Biol. 147: 207, 1991.
13. Cowin, A. J., Holmes, T. M., Brosnan, P., and Ferguson, M. W. Expression of TGF-beta and its receptors in murinefetal and adult dermal wounds. Eur. J. Dermatol. 11: 424, 2001.
14. Bullard, K. M., Longaker, M. T., and Lorenz, H. P. Fetal wound healing: Current biology. World J. Surg. 27: 54, 2003.
15. Bettinger, D. A., Yager, D. R., Diegelmann, R. F., and Cohen, I. K. The effect of TGF-beta on keloid fibroblast proliferation and collagen synthesis. Plast. Reconstr. Surg. 98: 827, 1996.
16. Younai, S., Nichter, L. S., Wellisz, T., Reinisch, J., Nimni, M. E., and Tuan, T. L. Modulation of collagen synthesis by transforming growth factor beta in keloid and hypertrophic scar fibroblasts. Ann. Plast. Surg. 33: 148, 1994.
17. Colwell, A. S., Phan, T. T., Kong, W., Longaker, M. T., and Lorenz, P. H. Hypertrophic scar fibroblasts have increased connective tissue growth factor expression after transforming growth factor-beta stimulation. Plast. Reconstr. Surg. 116: 1387, 2005.
18. Lee, T. Y, Chin, G S., Kim, W. J., Chan, D., Gittes, G K., and Longaker, M. T. Expression of transforming growth factor beta 1, 2 and 3 proteins in keloids. Ann. Plast. Surg. 43: 179, 1999.
19. Wang, X., Smith, P., Pu, L. L., Kim, Y.J., Ko, F., and Robson, M. C. Exogenous transforming growth factor beta 2 modulates collagen I and collagen III synthesis in proliferative scar xenografts in nude rats. J. Surg. Res. 87: 194, 1999.
20. Lanning, D. A., Nwomeh, B. C., Montante, S. J., Yager, D. R., Diegelmann, R. F., and Haynes, J. H. TGF-beta1 alters the healing of cutaneous fetal excisional wounds. J. Pediatr. Surg. 34: 695, 1999.
21. Polo, M., Smith, P. D., Kim, Y. J., Wang, X., Ko, F., and Robson, M. C. Effect of TGF-beta2 on proliferative scar fibroblast cell kinetics. Ann. Plast. Surg. 43: 185, 1999.
22. Peltonen, J., Kahari, L., Jaakkola, S., et al. Evaluation of transforming growth factor beta and type I procollagen gene expression in fibrotic skin diseases by in situ hybridization. J. Invest. Dermatol. 94: 365, 1990.
23. Verrecchia, F., Chu, M. L., and Mauviel, A. Identification of novel TGF-beta/Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J. Biol. Chem. 276: 17058, 2001.
24. Messadi, D. V., Berg, S., Sung-Cho, K., Lesavoy, M., and Bertolami, C. N. Autocrine transforming growth factor-beta(1) activity and glycosaminoglycan synthesis by human cutaneous scar fibroblasts. Wound Repair Regen. 2: 284, 1994.
25. Lu, L., Saulis, A. S., Liu, W. R., et al. The temporal effects of anti-TGF-beta1, 2, and 3 monoclonal antibody on wound healing and hypertrophic scar formation. J. Am. Coll. Surg. 201: 391, 2005.
26. Choi, B. M., Kwak, H. J., Jun, C. D., et al. Control of scarring in adultwounds using antisense transforming growth factor-beta 1 oligodeoxynucleotides. Immunol. Cell Biol. 74: 144, 1996.
27. Shah, M., Foreman, D. M., and Ferguson, M. W. Control of scarring in adult wounds by neutralising antibody to transforming growth factor. Lancet 339: 213, 1992.
28. Cordeiro, M. F., Mead, A., Ali, R., et al. Novel antisense oligonucleotides targeting TGF-beta inhibit in vivo scarring and improve surgical outcome. Gene Ther. 10: 59, 2003.
29. Brahmatewari, J., Serafini, A., Serralta, V., Mertz, P. M., and Eaglstein, W. H. The effects of topical transforming growth factor-beta2 and anti-transforming growth factor-beta2,3 on scarring in pigs. J. Cutan. Med. Surg. 4: 126, 2000.
30. Dovi, J. V., He, L. K., and DiPietro, L. A. Accelerated wound closure in neutrophil-depleted mice. J. Leukoc. Biol. 73: 448, 2003.
31. Martin, P., D'Souza, D., Martin, J., et al. Wound healing in the PU.1 null mouse: Tissue repair is not dependent on inflammatory cells. Curr. Biol. 13: 1122, 2003.
32. Wilgus, T. A., Ross, M. S., Parrett, M. L., and Oberyszyn, T. M. Topical application of a selective cyclooxygenase inhibitor suppresses UVB mediated cutaneous inflammation. Prostaglandins Other Lipid Mediat. 62: 367, 2000.
33. Talwar, M., Moyana, T. N., Bharadwaj, B., and Tan, L. K. The effect of a synthetic analogue of prostaglandin E2 on wound healing in rats. Ann. Clin. Lab. Sci. 26: 451, 1996.
34. Durant, S., Duval, D., and Homo-Delarche, F. Effect of exogenous prostaglandins and nonsteroidal anti-inflammatory agents on prostaglandin secretion and proliferation of mouse embryo fibroblasts in culture. Prostaglandins Leukot. Essent. Fatty Acids 38: 1, 1989.
35. Wilgus, T. A., Bergdall, V. K., Tober, K. L., et al. The impact of cyclooxygenase-2 mediated inflammation on scarless fetal wound healing. Am. J. Pathol. 165: 753, 2004.
36. Wilgus, T. A., Vodovotz, Y., Vittadini, E., Clubbs, E. A., and Oberyszyn, T. M. Reduction of scar formation in full-thickness wounds with topical celecoxib treatment. Wound Repair Regen. 11: 25, 2003.
37. Blomme, E. A., Chinn, K. S., Hardy, M., et al. Selective cyclooxygenase-2 inhibition does not affect the healing of cutaneous full-thickness incisional wounds in SKH-1 mice. Br. J. Dermatol. 148: 211, 2003.
38. Muller-Decker, K., Hirschner, W., Marks, F., and Furstenberger, G. The effects of cyclooxygenase isozyme inhibition on incisional wound healing in mouse skin. J. Invest. Dermatol. 119: 1189, 2002.
39. Kampfer, H., Brautigam, L., Geisslinger, G., Pfeilschifter, J., and Frank, S. Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair. J. Invest. Dermatol. 120: 880, 2003.
40. Kim, I., Mogford, J. E., Witschi, C., Nafissi, M., and Mustoe, T. A. Inhibition of prolyl 4-hydroxylase reduces scar hypertrophy in a rabbit model of cutaneous scarring. Wound Repair Regen. 11: 368, 2003.
41. Kubota, Y., Fujiwara, K., Ogata, I., Hori, Y., and Oka, H. Collagen prolyl hydroxylase inhibitor and reduced collagen formation in cotton pellet-induced granuloma and skin wound healing in rats. Br. J. Dermatol. 113: 559, 1985.
42. Panchenko, M. V., Stetler-Stevenson, W. G., Trubetskoy, O. V., Gacheru, S. N., and Kagan, H. M. Metalloproteinase activity secreted by fibrogenic cells in the processing of prolysyl oxidase: Potential role of procollagen C-proteinase. J. Biol. Chem. 271: 7113, 1996.
43. Reid, R. R., Mogford, J. E., Butt, R., DeGiorgio-Miller, A., and Mustoe, T. A. Inhibition of procollagen C-proteinase reduces scar hypertrophy in a rabbit model of cutaneous scarring. Wound Repair Regen. 14: 138, 2006.
44. Schnee, J. M., and Hsueh, W. A. Angiotensin II, adhesion, and cardiac fibrosis. Cardiovasc. Res. 46: 264, 2000.
45. Steckelings, U. M., Wollschlager, T., Peters, J., Henz, B. M., Hermes, B., and Artuc,M.Humanskin: Sourceofand target organ for angiotensin II. Exp. Dermatol. 13: 148, 2004.
46. Rodgers, K. E., Abiko, M., Girgis, W., Amand, K., Campeau, J. D., and Dizerega, G. S. Acceleration of dermal tissue repair by angiotensin II. Wound Repair Regen. 5: 175, 1997.
47. Takeda, H., Katagata, Y., Hozumi, Y., and Kondo, S. Effects of angiotensin II receptor signaling during skin wound healing. Am. J. Pathol. 165: 1653, 2004.
48. Okuyama, N., Roda, N., Sherman, R., et al. Effect of angiotensin II on the viability, vascularity of random flaps in a rat model. Ann. Plast. Surg. Res. 68: 913, 1999.
49. Morihara, K., Takai, S., Takenaka, H., et al. Cutaneous tissue angiotensin-converting enzyme may participate in pathologic scar formation in human skin. J. Am. Acad. Dermatol. 54: 251, 2006.
50. Steckelings, U. M., Henz, B. M., Wiehstutz, S., Unger, T., and Artuc, M. Differential expression of angiotensin receptors in human cutaneous wound healing. Br. J. Dermatol. 153: 887, 2005.
51. Suzuki, Y., Ruiz-Ortega, M., and Lorenzo, O. Inflammation and angiotensin II. Int. J. Biochem. Cell Biol. 35: 881, 2003.
52. Henry, S. L., Concannon, M. J., Kaplan, P. A., and Diaz-Arias, A. A. The inhibitory effect of minocycline on hypertrophic scarring. Plast. Reconstr. Surg. 120: 80, 2007.
53. Yrjanheikki, J., Tikka, T., Keinanen, R., Goldstein, G., Chan, P. H., and Koistinaho, J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc. Natl. Acad. Sci. U.S.A. 96: 13496, 1999.
54. Tamargo, R. J., Bok, R. A., and Brem, H. Angiogenesis inhibition by minocycline. Cancer Res. 51: 672, 1991.
55. Stoff, A., Rivera, A. A., Mathis, J. M., et al. Effect of adenoviral mediated overexpression of fibromodulin on human dermal fibroblasts and scar formation in full-thickness incisional wounds. J. Mol. Med. 85: 481, 2007.
56. Liu, W., Chua, C., Wu, X., et al. Inhibiting scar formation in rat wounds by adenovirus-mediated overexpression of truncated TGF-beta receptor II. Plast. Reconstr. Surg. 115: 860, 2005.
57. Reid, R. R., Roy, N., Mogford, J. E., Zimmerman, H., Lee, C., and Mustoe, T. A. Reduction of hypertrophic scar via retroviral delivery of a dominant negative TGF-beta receptor II. J. Plast. Reconstr. Aesthet. Surg. 60: 64, 2007.
58. Tang, Y. W. Intra and postoperative steroid injections for keloids and hypertrophic scars. Br. J. Plast. Surg. 45: 371, 1992.
59. Manuskiatti, W., and Fitzpatrick, R. Treatment response of keloidal and hypertrophic sternotomy scars. Arch. Dermatol. 138: 1149, 2002.
60. Darzi, M. A., Chowdri, N. A., Kaul, S. K., and Khan, M. Evaluation of various methods of treating keloids and hypertrophic scars: A 10-year follow-up study. Br. J. Plast. Surg. 45: 374, 1992.
61. Fassler, R., Sasaki, T., Timpl, R., Chu, M. L., and Werner, S. Differential regulation of fibulin, tenascin-C, and nidogen expression during wound healing of normal and glucocorticoid-treated mice. Exp. Cell Res. 222: 111, 1996.
62. Perez, P., Page, A., Bravo, A., et al. Altered skin development and impaired proliferative and inflammatory responses in transgenic mice overexpressing the glucocorticoid receptor. F.A.S.E.B. J. 15: 2030, 2001.
63. Wu, W. S., Wang, F. S., Yang, K. D., Huang, C. C., and Kuo, Y. R. Dexamethasone induction of keloid regression through effective suppression of VEGF expression and ke-loid fibroblast proliferation. J. Invest. Dermatol. 126: 1264, 2006.
64. Stojadinovic, O., Lee, B., Vouthounis, C., et al. Novel genomic effects of glucocorticoids in epidermal keratino-cytes: Inhibition of apoptosis, interferon-gamma pathway, and wound healing along with promotion of terminal differentiation. J. Biol. Chem. 282: 4021, 2007.
65. Manuskiatti, W., and Fitzpatrick, R. E. Treatment response of keloidal and hypertrophic sternotomy scars: Comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Arch. Dermatol. 138: 1149, 2002.
66. Maguire, H. C. Treatment of keloids with triamcinolone acetonide injected intralesionally. J.A.M.A. 192: 325, 1956.
67. Asilian, A., Darougheh, A., and Shariati, F. New combination of triamcinolone, 5-fluorouracil, and pulsed-dye laser for treatment of keloid and hypertrophic scars. Dermatol. Surg. 32: 907, 2006.
68. Alster, T. S. Laser scar revision: Comparison study of 585-nm pulsed dye laser with and without intralesional corticosteroids. Dermatol. Surg. 29: 25, 2003.
69. Fitzpatrick, R. E. Treatment of inflamed hypertrophic scars using intralesional 5-FU. Dermatol. Surg. 25: 224, 1999.
70. Gupta, S., and Kalra, A. Efficacy and safety of intralesional 5-fluorouracil in the treatment of keloids. Dermatology 204: 130, 2002.
71. Nanda, S., and Reddy, B. S. Intralesional 5-fluorouracil as a treatment modality of keloids. Dermatol. Surg. 30: 54, 2004.
72. Kontochristopoulos, G., Stefanaki, C., Panagiotopoulos, A., et al. Intralesional 5-fluorouracil in the treatment of keloids: An open clinical and histopathologic study. J. Am. Acad. Dermatol. 52: 474, 2005.
73. Friedman, S. J., Butler, D. R., and Dittelkov, M. R. Perilesional linear atrophy and hypopigmentation after intralesional corticosteroid therapy. J. Am. Acad. Dermatol. 19: 537, 1988.
74. Mallick, K. S., Hajek, A. S., and Parrish, R. K., II. Fluorouracil (5-FU) and cytarabine (ara-C) inhibition of corneal epithelial cell and conjunctival fibroblast proliferation. Arch. Ophthalmol. 103: 1398, 1985.
75. Blumenkranz, M. S., Ophir, A., Claflin, A. J., and Hajek, A. Fluorouracil for the treatment of massive periretinal proliferation. Am. J. Ophthalmol. 94: 458, 1982.
76. Wendling, J., Marchand, A., Mauviel, A., and Verrecchia, F. 5-Fluorouracil blocks transforming growth factor-beta-induced alpha 2 type I collagen gene (COL1A2) expression in human fibroblasts via c-Jun NH2-terminal kinase/activator protein-1 activation. Mol. Pharmacol. 64: 707, 2003.
77. Crooke, S. T., and Bradner, W. T. Bleomycin, a review. J. Med. 7: 333, 1976.
78. Saray, Y., and Güleç, A. T. Treatment of keloids and hypertrophic scars with dermojet injections of bleomycin: A preliminary study. Int. J. Dermatol. 44: 777, 2005.
79. Naeini, F. F., Najafian, J., and Ahmadpour, K. Bleomycin tattooing as a promising therapeutic modality in large ke-loids and hypertrophic scars. Dermatol. Surg. 32: 1023, 2006.
80. España, A., Solano, T., and Quintanilla, E. Bleomycin in the treatment of keloids and hypertrophic scars by multiple needle punctures. Dermatol. Surg. 27: 23, 2001.
81. Hendricks, T., Martens, M. F., Huyben, C. M., et al. Inhibition of basal and TGF beta-induced fibroblast collagen synthesis by antineoplastic agents: Implications for wound healing. Br. J. Cancer 67: 545, 1993.
82. Lee, K. S., Song, J. Y., and Suh, M. H. Collagen mRNA expression detected by in situ hybridization in keloid tissue. J. Dermatol. Sci. 2: 316, 1991.
83. Bodokh, I., and Brun, P. Treatment of keloid with intralesional bleomycin. Ann. Dermatol. Venereol. 123: 791, 1996.
84. Alster, T. S., and Williams, C. M. Treatment of keloid ster-notomy scars with 585 nm flashlamp-pumped pulsed-dye laser. Lancet 345: 1198, 1995.
85. Alster, T. S. Improvement of erythematous and hypertrophic scars by the 585 nm flash lamp pulsed dye laser. Ann. Plast. Surg. 31: 1, 1993.
86. Reiken, S. R., Wolfort, S. F., Berthiamume, F., Compton, C., Tompkins, R. G., and Yarmush, M. L. Control of hypertrophic scar growth using selective photothermolysis. Lasers Surg. Med. 21: 7, 1997.
87. Lupton, J. R., and Alster, T. S. Laser scar revision. Dermatol. Clin. 20: 55, 2002.
88. Quinn, K. J. Silicone gel in scar treatment. Burns 13: S33, 1987.
89. Carney, S. A., Cason, C. G., Gowar, J. P., et al. Cica-Care gel sheeting in the management of hypertrophic scarring. Burns 20: 163, 1994.
90. Ahn, S., Monafo, W. W., and Mustoe, T. A. Topical silicone gel for the prevention and treatment of hypertrophic scar. Arch. Surg. 126: 499, 1991.
91. Cruz-Korchin, N. I. Effectiveness of silicone sheets in the prevention of hypertrophic breast scars. Ann. Plast. Surg. 37: 345, 1996.
92. Neissen, F. B., Spauwen, P. H. M., Robinson, P. H., Fidler, V., and Kon, M. The use of silicone occlusive sheeting (Sil-K) and silicone occlusive gel (Epiderm) in the prevention of hypertrophic scar formation. Plast. Reconstr. Surg. 102: 1962, 1998.
93. O'Brien, L., and Pandit, A. Silicon gel sheeting for preventing and treating hypertrophic and keloid scars. Cochrane Database Syst. Rev. 1: CD003826, 2006.
94. Chang, C. C., Kuo, Y. F., Hsien-Ching, C., Lee, J. L., Wong, T. W., and Jee, S. H. Hydration, not silicone, modulates the effects of keratinocytes on fibroblasts. J. Surg. Res. 59: 705, 1995.
95. Tolhurst, D. Hypertrophic scarring prevented by pressure: A case report. Br. J. Plast. Surg. 30: 218, 1977.
96. Chang, P., Laubenthal, K. N., Lewis, R. W., II, Rosenquist, M. D., Lindley-Smith, P., and Kealey, G. P. Prospective, randomized study of the efficacy of pressure garment therapy in patients with burns. J. Burn Care Rehabil. 16: 473, 1995.
97. Har-Shai, Y., Amar, M., and Sabo, E. Intralesional cryother-apy for enhancing the involution of hypertrophic scars and keloids. Plast. Reconstr. Surg. 111: 1841, 2003.
98. Zouboulis, C. C., Blume, U., Büttner, P., and Orfanos, C. E. Outcomes of cryosurgery in keloids and hypertrophic scars: A prospective consecutive trial of case series. Arch. Dermatol. 129: 1146, 1993.
99. Har-Shai, Y., Amar, M., and Sabo, E. Intralesional cryother-apy for enhancing the involution of hypertrophic scars and keloids. Plast. Reconstr. Surg. 111: 1841, 2003.
100. Rusciani, L., Rossi, G., and Bono, R. Use of cryotherapy in the treatment of keloids. J. Dermatol. Surg. Oncol. 19: 529, 1993.
101. Rusciani, L., Paradisi, A., Alfano, C., Chiummariello, S., and Rusciani, A. Cryotherapy in the treatment of keloids. J. Drugs Dermatol. 5: 591, 2006.
102. Ragoowansi, R., Cornes, P. G., Moss, A. L., and Glees, J. P. Treatment of keloids by surgical excision and immediate postoperative single-fraction radiotherapy. Plast. Reconstr. Surg. 111: 1853, 2003.
103. Ship, A. G, Weiss, P. R., Mincer, F. R., and Wolkstein, W. Sternal keloids: Successful treatment employing surgery and adjunctive radiation. Ann. Plast. Surg. 31: 481, 1993.
104. Berman, B., and Bieley, H. C. Adjunct therapies to surgical management of keloids. Dermatol. Surg. 22: 126, 1996.
105. Kovalic, J. J., and Perez, C. A. Radiation therapy following keloidectomy: A 20-year experience. Int. J. Radiat. Oncol. Biol. Phys. 17: 77, 1989.
106. Shah, M., Foreman, D. M., and Ferguson, M. W. Neutralisation of TGF-β1 and TGF-β2 or exogenous addition of TGF-β3 to cutaneous rat wounds reduces scarring. J. Cell Sci. 108: 985, 1995.
107. McCoy, B. J., Diegelmann, R. F., and Cohen, I. K. In vitro inhibition of cell growth, collagen synthesis and prolyl hydroxylase activity by triamcinolone acetonide. Proc. Soc. Exp. Biol. Med. 163: 216, 1980.
108. Kuo, Y. R., Jeng, S. F., Wang, F. S., et al. Flashlamp pulsed dye laser (PDL) suppression of keloid proliferation through down-regulation of TGF-beta1 expression and extracellular matrix expression. Lasers Surg. Med. 34: 104, 2004.
109. Kuo, Y. R., Wu, W. S., Jeng, S. F., et al. Suppressed TGF-beta1 expression is correlated with up-regulation of matrix metalloproteinase-13 in keloid regression after flashlamp pulsed-dye laser treatment. Lasers Surg. Med. 36: 38, 2005.
110. Tandara, A. A., Kloeters, O., Mogford, J. E., and Mustoe, T. A. Hydrated keratinocytes reduce collagen synthesis by fibroblasts via paracrine mechanisms. Wound Repair Regen. 15: 497, 2007.
111. Kuhn, M. A., Moffit, M. R., Smith, P. D., et al. Silicone sheeting decreases fibroblast activity and downregulates TGFbeta2 in hypertrophic scar model. Int. J. Surg. Invest. 2: 467, 2001.
112. Kischer, C. W., Shetlar, M. R., and Shetlar, C. L. Alteration of hypertrophic scars inducedbymechanical pressure. Arch. Dermatol. 111: 60, 1975.
113. Dalkowski, A., Fimmel, S., Beutler, C., and Zouboulis, ChC. Cryotherapy modifies synthetic activity and differentiation of keloidal fibroblasts in vitro. Exp. Dermatol. 12: 673, 2003.
114. Rusciani, L., Rossi, G., and Bono, R. Use of cryotherapy in the treatment of keloids. J. Dermatol. Surg. Oncol. 19: 529, 1993.
115. Zouboulis, C.C., Blume, U., Büttner, P., and Orfanos, C. E. Outcomes of cryosurgery in keloids and hypertrophic scars: A prospective consecutive trial of case series. Arch. Dermatol. 129: 1146, 1993.